Cytek Biosciences (CTKB) risk factors, FY2025 10-K

Risks Related to Our Business and Strategy

1. 01We have a limited operating history and only recently launched our commercial products, which may make it difficult to evaluate the prospects for our future viability and predict our future performance. We have limited experience marketing and selling our products
2. 02We are highly dependent on a limited number of product offerings. Our revenue has been primarily generated from sales of our core Cytek Aurora, Northern Lights, Cytek Aurora CS, and Cytek Aurora Evo systems, which require a substantial sales cycle and are prone to quarterly fluctuations in revenue
3. 03Our results of operations will be harmed if we are unable to accurately forecast customer demand for our products and manage our inventory
4. 04International operations and expansion of our international business expose us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States
5. 05Tariffs or other government trade policies may materially adversely affect our business and results of operations, including by reducing demand for our products87% rewritten
6. 06The complexity of announced or future tariffs may also increase the risk that we or our customers or suppliers may be subject to civil or criminal enforcement actions in the United States or foreign jurisdictions related to compliance with trade regulationsNew
7. 07We are subject to governmental export controls and sanctions programs that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws
8. 08We have limited experience manufacturing our products, and if we are unable to manufacture our products in high-quality commercial quantities successfully and consistently to meet demand, our growth will be limited
9. 09Our future success is dependent upon our ability to increase penetration in our existing markets and expand into adjacent markets49% rewritten
10. 10unwilling to change current practices to adopt our products, it will negatively affect our business, financial condition, prospects and results of operationsNew
11. 11Our business currently depends significantly on research and development spending by academic and government-owned institutions, a reduction in which could limit demand for our solutions and adversely affect our business and operating results47% rewritten
12. 12We rely on distributors for sales of our products in certain geographies outside of the United States. If we are unable to secure additional distributors or maintain good relationships with our existing distributors, or if such distributors do not perform adequately or effectively, our business could suffer
13. 13The market for cell analysis technologies and life sciences tools, including flow cytometry, is highly competitive, and if we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue, or achieve and sustain profitability
14. 14Our future success depends on our ability to develop and successfully introduce new and enhanced products that meet the needs of our customers36% rewritten
15. 15our customers’ needs or otherwise fail to obtain desired levels of market acceptance, our business may suffer and our operating results could be adversely affectedNew
16. 16New product development involves a lengthy and complex process and we may be unable to develop or commercialize products on a timely basis, or at all
17. 17Our product development processes involve a high degree of risk, and these efforts may be delayed or fail for many reasons, including failure of the product to perform as expected and failure to reliably demonstrate the advantages of the product66% rewritten
18. 18replacement costs differ significantly from our estimates, adjustments to cost of sales may be required in future periods which could have an adverse effect on our results of operationsNew
19. 19We may acquire other businesses or form other joint ventures or make investments in other companies or technologies that could negatively affect our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense
20. 20Shipping is a critical part of our business and any changes in our shipping arrangements or damages or losses sustained during shipping could adversely affect our business, financial condition, results of operations and prospects
21. 21If we are unable to successfully expand our commercial operations, including hiring additional qualified sales representatives, technical applications specialists and customer support staff, our business may be adversely affected
22. 22If we are unable to expand or leverage the number of peer-reviewed articles published using data generated by our products or otherwise increase brand awareness, the demand for our products and our business may be adversely affected
23. 23We are highly dependent on our senior management team and key personnel and our business could be harmed if we are unable to attract and retain personnel necessary for our success
24. 24We have increased the size of our organization and expect to further increase it in the future, and we may experience difficulties in managing our growth. If we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed66% rewritten
25. 25If we fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operationsNew
26. 26We may need to raise additional capital to fund our existing operations, develop our products and/or expand our operations
27. 27Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide
28. 28The sizes of the markets for our products may be smaller than we estimate
29. 29If we were to be sued for product liability, we could face substantial liabilities that exceed our resources, limit sales of our existing products and limit commercialization of any products that we may develop
30. 30Litigation and other legal proceedings may harm our business58% rewritten
31. 31disruptions of our business. Threat actors may also gain access to other networks and systems after a compromise of our networks and systemsNew
32. 32Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
33. 33Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities58% rewritten
34. 34regulations, which can be expensive and restrict how we do business, and could expose us to liability if our use of such hazardous materials cause injuryNew
35. 35We are subject to foreign currency exchange risk

Risks Related to Government Regulation and Our Industry

1. 36We and our suppliers are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements
2. 37Our products or any component thereof may be subject to product recalls in the future. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on us
3. 38The misuse or off-label use of our products may harm our reputation in the marketplace, or result in injuries that lead to product liability suits, which could be costly to our business. Moreover, we could be subject to FDA sanctions if we are deemed to have engaged in off-label promotion
4. 39expensive to defend and could divert our management’s attention from our primary business and result in substantial damage awards against us. Any of these events could harm our business, results of operations and financial conditionNew
5. 40FDA have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictableNew
6. 41Issues in the development and use of artificial intelligence technologies, combined with an uncertain regulatory environment, may result in reputation harm, liability, or other adverse consequences to our business operationsNew
7. 42If we fail to comply with U.S. federal and state fraud and abuse and other healthcare laws and regulations, including those relating to kickbacks and false claims, we could face substantial penalties and our business operations and financial condition could be harmed
8. 43Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could harm our business, financial condition and results of operations

Risks Related to Our Intellectual Property

1. 44existing intellectual property rights we have, we may have to abandon development of the relevant products, which could harm our business, financial condition and results of operationsNew
2. 45Patents covering our current, and any future, products or our technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, which could harm our business, financial condition and results of operations
3. 46We rely substantially on our trademarks and trade names. If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be harmed74% rewritten
4. 47Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our current and any future products69% rewritten
5. 48Third-party claims of intellectual property infringement, misappropriation or other violation against us, the joint-owners of our intellectual property, or our collaborators may prevent or delay the sale and marketing of our current and any future products
6. 49We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful
7. 50If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
8. 51Failure of a key information technology system, process, or site could have an adverse effect on our business
9. 52Our use of open source software could compromise our ability to offer our services and subject us to possible litigation

Risks Related to Ownership of Our Common Stock

1. 53Our stock price may continue to be volatile, and our stockholders may not be able to resell shares of our common stock at or above the price they paid
2. 54We have broad discretion in the use of our cash and may invest or spend the funds in ways with which you do not agree and in ways that may not yield a return
3. 55Substantial future sales of shares of our common stock or securities convertible into our common stock will result in additional dilution of the percentage of ownership of our stockholders and could cause the market price of our common stock to decline41% rewritten
4. 56Concentration of ownership of our common stock among our executive officers, directors, and principal stockholders and their respective affiliates may prevent new investors from influencing significant corporate decisions
5. 57We do not intend to pay dividends for the foreseeable future and, as a result, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock
6. 58Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud72% rewritten
7. 59recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are metNew
8. 60Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management53% rewritten
9. 61the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court’s having personal jurisdiction over the indispensable parties named as defendantsNew
10. 62We could be subject to securities class action litigation
11. 63We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance with our public company responsibilities and corporate governance practices
12. 64Our failure to meet Nasdaq’s continued listing requirements could result in a delisting of our common stock
13. 65If securities or industry analysts do not publish research or publish unfavorable or inaccurate research about our business, our common stock price and trading volume could decline
14. 66Our ability to use our net operating losses (“NOLs”) to offset future taxable income may be subject to certain limitations49% rewritten
15. 67Changes in our effective tax rate or tax liability may have an adverse effect on our results of operations
16. 68Changes in tax law and regulations may have a material adverse effect on our business, financial condition and results of operations37% rewritten
17. 69Changes and uncertainties in the tax system in the countries in which we have operations, could materially adversely affect our financial condition and results of operations, and reduce net returns to our shareholders